Compare Ginkgo Bioworks Holdings Inc (DNA) vs The Coca-Cola Co K (KO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs The Coca-Cola Co K — how do they compare? Ginkgo Bioworks Holdings Inc trades at $11.57 (market cap $772.39M), while The Coca-Cola Co K trades at $87.3 (market cap $369.24B). The key difference: The Coca-Cola Co K is far larger — about 478× Ginkgo Bioworks Holdings Inc's market cap, and The Coca-Cola Co K pays a 2.47% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and The Coca-Cola Co K for 154 Days on average.
| DNA | KO | |
|---|---|---|
Market Cap | $772.39M | $369.24B |
Volume | 6,453,273 | 12,951,290 |
Sector | Health | Consumer Staples |
52-Week High | $15.83 | $91.99 |
52-Week Low | $5.48 | $66.37 |
Typical Hold Time | 7 Days | 154 Days |
Enterprise Value | $874.34M | $396.42B |
Dividend Yield | — | 2.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $11.47, down 7.57% on the day, with a bullish technical signal from moving averages but mixed earnings performance. The company reported a net loss of $312.76 million on $170.16 million revenue in 2025, with a high gross margin of 68.04% but negative net income margin. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting growth initiatives amid financial challenges.
The outlook remains speculative with significant cash burn and persistent losses, though partnerships and government contracts offer potential catalysts. Risks include high operating costs and reliance on funding, while analyst sentiment is divided equally between buy, hold, and sell ratings. Investment hinges on the company's ability to monetize its technology and achieve profitability.
Coca-Cola (KO) trades at $87.77, up 1.86% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 28.56% net income margin and 44.23% ROE, supported by consistent revenue growth. Analyst consensus is bullish with a $95.75 price target, though technical indicators highlight near-term resistance at $86-$87. Recent news highlights institutional buying and stable demand trends ahead of Q3 earnings.
The outlook remains positive given KO's dividend track record and earnings momentum, but risks include regional demand volatility and high debt levels. Upside is supported by analyst targets, while technical weakness near key resistance may limit short-term gains. The stock offers value for income-focused investors despite macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About The Coca-Cola Co K
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →
